We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy insider buying in 2025.
Insider trading is often seen as an important indicator of management’s confidence in their company’s future. For decades, top investors and analysts have endorsed this idea, arguing that insiders purchase shares of their own companies for one primary reason – if they firmly believe the stock price will increase significantly and grow the value of their investment. This idea stems from the fact that insiders, such as high ranked executives and directors, possess confidential information and data that helps them draw insights into the company’s outlook and growth trajectory well before outside investors are able to. As a result, empirical research on the topic tends to agree that insider buying coincides with troughs in stock prices, and vice versa, insider selling coincides with peak valuations.
READ ALSO: 12 Penny Stocks with Insider Buying in 2025
The US stock market has experienced two years of explosive growth, following the 2022 bear market fueled by rising inflation and interest rates. For most of 2023, the stock market appreciation was primarily driven by a small subset of companies fueled by AI-related tailwinds, which led to rising concentration levels, all while on an equal-weighted basis, the performance was staying flat. The following year brought a broader acceleration in growth, with many other sectors catching up and driving a new all-time high into early 2025. We can now firmly say that the bear market of 2023-2024 has been broad, leading to apparently expensive valuations across the entire market. It is certainly not easy to be an investor in the US market right now, as peak valuations make most of the companies appear expensive, all while new threats and risks loom from all directions.
The new US administration has brought a major change in trajectory, something which hasn’t been seen in decades. Many of their new policies are a short-term (at least) threat to several industries and sectors, ranging from Medicare/Medicaid reimbursements and ending with Government consulting, engineering, and technology contractors. A more recent development, which arises as a result of the new Government policies, is a potential slowdown in commercial and residential construction – the freshly imposed tariffs are a major headwind for builders, as they make building materials significantly more expensive, all while the heightened scrutiny on immigration can potentially cause labor shortages in this field, which again makes building more expensive. The key takeaway is that plenty of new risks arise every day, which, coupled with still near peak valuations, makes it difficult for investors to decide which stocks to invest in.
With that being said, we believe insider buying could provide unique insights into what more informed investors (management itself) believe will happen with the stock price of their company. Sudden developments often bring overreactions from investors, which create opportunities for more informed investors to act. In this context, closely watching insider buying could provide a strong signal that the market overreacted to some negative developments. Also, we believe that the larger the amount of stock an insider is buying, the stronger the insider’s conviction in the future of the company. That’s why we decided to particularly track companies that have shown heavy insider buying in the last couple of months.
Our Methodology
We used Insider Monkey’s insider trading stock screener to find companies with at least two insiders buying shares worth at least $500,000 in the last six months. We believe that multiple insiders buying significant amounts of stock represents a higher chance that insiders have high confidence in the company. For all the companies we also include the number of hedge funds that own the stock, according to Insider Monkey’s database of Q4 2024. The stocks are ranked according to hedge funds having stakes in them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A pharmacist in a white coat with a range of drugs on shelves behind her.
Biohaven Ltd. (NYSE:BHVN)
Number of Hedge Fund Holders: 41
Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric diseases. The company’s portfolio includes therapies targeting conditions such as spinocerebellar ataxia, amyotrophic lateral sclerosis, and multiple system atrophy. BHVN leverages proprietary technology platforms to advance its drug development pipeline. Following its spin-off in October 2022, BHVN has been actively pursuing clinical studies and collaborations to bring novel therapies to patients with unmet medical needs.
Biohaven Ltd. (NYSE:BHVN) reported positive topline results in their 3-year study of troriluzole for treating spinocerebellar ataxia (SCA), demonstrating a 50% slowing in disease progression on the study’s primary outcome measure. The treatment resulted in a significant 1.5-year treatment gain over the course of the 3-year study, with efficacy demonstrated across 9 prespecified outcome measures while maintaining a safe and well-tolerated profile. Based on these results, the company plans to submit a new drug application to the FDA for troriluzole in treating all SCA genotypes by the end of the year, with expectations for an accelerated review based on previously granted orphan drug and fast-track designations.
The commercial opportunity for Biohaven Ltd. (NYSE:BHVN) is substantial, with approximately 15,000 people affected by SCA in the US and 24,000 in Europe and the UK, representing both a high unmet need and a large commercial market. The company has strong IP protection with NCE composition of matter patent expiration anticipated in 2041 with extensions. The treatment demonstrated remarkable efficacy, showing a 50% to 70% slowing of disease progression over 3 years, reflecting a 1.5- to 2.2-year delay in SCA decline across different analysis cohorts. Additionally, troriluzole showed a 53% reduction in relative risk of falls in treated patients, with an even more pronounced 60% reduction in ambulatory patients. The strong opportunities for BHVN are further reinforced by at least two insiders buying more than $500,000 worth of company stock in the last six months.
Overall, BHVN ranks 3rd on our list of stocks with heavy insider buying in 2025. While we acknowledge the potential of BHVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
